IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
Open Access
Abstract
The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world. We collected blood samples from 132 PLWH aged 18–59 years who were vaccinated with two doses of BBIBP-CorV vaccine (Sinopharm) or CoronaVac vaccine (SinoVac) at 28 ± 7 days and 180 ± 20 days the after second dose, to detect the level of Spike receptor binding domain-protein specific IgG (S-RBD-IgG) by using chemiluminescence. We found that the BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody seropositivity rates and levels in PLWH than in healthy controls (HCs). The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower humoral immune responses in PLWH, having lower CD4+T cell counts (+T cell counts (≥350 cells/μL) after a second dose of vaccination. The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody levels in PLWH, having CD4+T cell counts ≥350 cells/μL compared to HCs. No negative effects were observed in terms of the CD4+T cell counts and HIV RNA viral load (VL) of PLWH after vaccination. Ninety-nine PLWH and eighty-three HCs completed a second blood collection for testing; we found a statistically significant decrease in the humoral immune response both in PLWH and HCs from 28 days to 180 days after a second dose of BBIBP-CorV vaccine or CoronaVac vaccine. The S-RBD-IgG antibody induced by the BBIBP-CorV vaccine or the CoronaVac vaccine declined faster in the PLWH population than in the healthy population, and two doses of the BBIBP-CorV vaccine or the CoronaVac vaccine may not be enough to provide PLWH with persistent immunity against SARS-CoV-2. It is necessary for PLWH to be prioritized for a third dose over the healthy population, but the immunogenicity of the third dose of the homologous or heterologous vaccine requires further study.Keywords
Funding Information
- Shenzhen Municipal Science and Technology Innovation Committee Foundation (JCYJ20180508152244835, 2019B1515120003)
- Guangdong Provincial Basic and Applied Basic Research Foundation (JCYJ20180508152244835, 2019B1515120003)
This publication has 22 references indexed in Scilit:
- Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individualsmedRxiv, 2021
- Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272International Journal of Infectious Diseases, 2021
- COVID-19 Vaccines for HIV-Infected PatientsViruses, 2021
- A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2medRxiv, 2021
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialThe Lancet HIV, 2021
- SARS-CoV-2 Spike Antibody Levels Trend among Sinopharm Vaccinated PeopleIranian Journal of Public Health, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune SystemFrontiers in Immunology, 2020
- Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infectionCurrent Opinion in HIV and AIDS, 2019
- Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-AnalysisClinical Infectious Diseases, 2014